Policy & Regulations

This channel includes news coverage of healthcare policy and regulations set by Congress, the states, Centers for Disease Control and Prevention (CDC), the Department of Health and Human Services (HHS), U.S. Food and Drug Administration (FDA), and medical associations and societies. 

Thumbnail

AMA votes no on Medicare for all

As Medicare for all continues to gain traction among American voters and more Democratic presidential nominees take up the platform, the American Medical Association has decided not to support such an initiative.

Thumbnail

HHS expands health reimbursement coverage

HHS, with the Departments of Labor and Treasury, has issued a new rule to expand the use of health reimbursement coverage, which provide tax-preferred funds for employees to buy their own insurance on the individual market.

Thumbnail

Huffington Post highlights the GoFundMe reality of healthcare costs

The sky-high costs of receiving medical care and the reality of asking for help to pay those bills are being highlighted by The Huffington Post in a series titled “Life and Death: Stories from Inside America’s GoFundMe Health Care System.”

Thumbnail

CMS asks for input in efforts to reduce paperwork

CMS wants to reduce the paperwork burden for the healthcare industry and is asking for stakeholder input on its initiative, Patients over Paperwork, the agency announced June 6.

 

Thumbnail

Washington Post: Pfizer hid effectiveness of drug to reduce Alzheimer’s risk

Drugmaker Pfizer hid that one of its powerful anti-inflammatory drugs for rheumatoid arthritis therapy, Enbrel, reduced the risk of Alzheimer’s disease by 64%, according to a report by the Washington Post.

 

Thumbnail

Partners Healthcare won’t buy Care New England

Partners HealthCare, a Boston-based health system, has backed out of its planned acquisition of Care New England

Thumbnail

CVS to expand HealthHub concept

Amid an ongoing court review of its $69 billion merger with health insurer Aetna, CVS Health isn’t slowing down in its plans to expand, according to executives who spoke at the company’s investor day on June 4.

 

Thumbnail

Top-selling drugs keep rising in price

Brand-name drugs are likely to keep rising in price, even though the top-selling ones have been available for years and have already seen their costs skyrocket, according to a new study published in JAMA.

 

Around the web

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Trimed Popup
Trimed Popup